In patients with primary breast cancer, treatment associated bone loss can occur either with adjuvant endocrine therapy (e.g., aromatase inhibitors), or in patients with a reduction of ovarian function due to surgery or chemotherapy. This evidence concerns the gene CYP19A1 and breast carcinoma.